Billiontoone (NASDAQ:BLLN) Stock: Insider Oguzhan Atay Sells 5,150 Shares

Key Points

• CEO Oguzhan Atay sold 5,150 Billiontoone shares for approximately $516,185 under a pre-arranged Rule 10b5-1 plan, reducing his direct holdings by 61.8% to 3,183 shares.
• BLLN shares fell $4.61 to $98.12, giving the company a market capitalization of about $4.63 billion and a P/E ratio of 146.76.
• Analysts maintain a consensus “Moderate Buy” rating with a $126.25 price target, although several firms recently lowered their targets or downgraded the stock.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) CEO Oguzhan Atay sold 5,150 shares of the firm's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $100.23, for a total value of $516,184.50. Following the completion of the sale, the chief executive officer directly owned 3,183 shares of the company's stock, valued at approximately $319,032.09. This represents a 61.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Wednesday, October 14th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $261,366.00.
• On Wednesday, October 14th, Oguzhan Atay sold 3,183 shares of Billiontoone stock. The shares were sold at an average price of $98.34, for a total transaction of $313,016.22.
• On Monday, October 12th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $97.61, for a total transaction of $260,325.87.
• On Monday, October 12th, Oguzhan Atay sold 16,667 shares of Billiontoone stock. The shares were sold at an average price of $93.79, for a total transaction of $1,563,197.93.
• On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total transaction of $321,626.24.
• On Monday, September 28th, Oguzhan Atay sold 8,333 shares of Billiontoone stock. The stock was sold at an average price of $120.64, for a total transaction of $1,005,293.12.
• On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total transaction of $522,536.00.
• On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The stock was sold at an average price of $100.32, for a total transaction of $2,507,899.68.
• On Monday, August 3rd, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $137.37, for a total transaction of $1,717,125.00.
• On Monday, August 3rd, Oguzhan Atay sold 32,500 shares of Billiontoone stock. The shares were sold at an average price of $136.95, for a total transaction of $4,450,875.00.

Billiontoone Stock Performance

Shares of NASDAQ BLLN traded down $4.61 during midday trading on Friday, reaching $98.12. The company had a trading volume of 605,635 shares, compared to its average volume of 654,157. The business's 50-day simple moving average is $100.99 and its 200 day simple moving average is $101.58. The stock has a market cap of $4.63 billion and a P/E ratio of 146.76. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $150.44. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17.

Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting the consensus estimate of $0.15. The business had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. On average, analysts forecast that Billiontoone, Inc. will post 0.80 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on BLLN shares. Weiss Ratings downgraded Billiontoone from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, October 8th. Zacks Research raised Billiontoone from a "strong sell" rating to a "hold" rating in a report on Friday, October 2nd. JPMorgan Chase & Co. reduced their price objective on Billiontoone from $145.00 to $130.00 and set an "overweight" rating for the company in a research note on Thursday, August 6th. Wall Street Zen cut Billiontoone from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, BTIG Research decreased their target price on Billiontoone from $142.00 to $130.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $126.25.

Institutional Trading of Billiontoone

Several large investors have recently made changes to their positions in BLLN. Integrated Wealth Concepts LLC purchased a new position in shares of Billiontoone during the second quarter worth $29,000. Toth Financial Advisory Corp boosted its holdings in Billiontoone by 60.0% in the third quarter. Toth Financial Advisory Corp now owns 800 shares of the company's stock valued at $85,000 after purchasing an additional 300 shares during the last quarter. MCF Advisors LLC boosted its holdings in Billiontoone by 330.8% in the second quarter. MCF Advisors LLC now owns 448 shares of the company's stock valued at $54,000 after purchasing an additional 344 shares during the last quarter. Family Legacy Financial Solutions LLC acquired a new stake in Billiontoone during the 3rd quarter worth about $53,000. Finally, Thrive Wealth Management LLC acquired a new stake in Billiontoone during the 2nd quarter worth about $240,000.

Billiontoone Company Profile

BillionToOne, Inc NASDAQ: BLLN is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company's platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne's primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.